EP1089732A4 - Compositions and methods for treating elevated blood cholesterol - Google Patents

Compositions and methods for treating elevated blood cholesterol

Info

Publication number
EP1089732A4
EP1089732A4 EP99930452A EP99930452A EP1089732A4 EP 1089732 A4 EP1089732 A4 EP 1089732A4 EP 99930452 A EP99930452 A EP 99930452A EP 99930452 A EP99930452 A EP 99930452A EP 1089732 A4 EP1089732 A4 EP 1089732A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
blood cholesterol
elevated blood
treating elevated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99930452A
Other languages
German (de)
French (fr)
Other versions
EP1089732A1 (en
Inventor
Alfred A Reszka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9817174.7A external-priority patent/GB9817174D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1089732A1 publication Critical patent/EP1089732A1/en
Publication of EP1089732A4 publication Critical patent/EP1089732A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99930452A 1998-06-24 1999-06-21 Compositions and methods for treating elevated blood cholesterol Withdrawn EP1089732A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9040498P 1998-06-24 1998-06-24
US90404P 1998-06-24
GB9817174 1998-08-06
GBGB9817174.7A GB9817174D0 (en) 1998-08-06 1998-08-06 Compositions and methods for treating elevated blood cholesterol
PCT/US1999/013888 WO1999066930A1 (en) 1998-06-24 1999-06-21 Compositions and methods for treating elevated blood cholesterol

Publications (2)

Publication Number Publication Date
EP1089732A1 EP1089732A1 (en) 2001-04-11
EP1089732A4 true EP1089732A4 (en) 2001-09-19

Family

ID=26314177

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99930452A Withdrawn EP1089732A4 (en) 1998-06-24 1999-06-21 Compositions and methods for treating elevated blood cholesterol

Country Status (5)

Country Link
EP (1) EP1089732A4 (en)
JP (1) JP2002518449A (en)
AU (1) AU4699099A (en)
CA (1) CA2336192A1 (en)
WO (1) WO1999066930A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492170B1 (en) 2000-09-11 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 9 expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
AU2001295991A1 (en) * 2000-10-23 2002-05-06 Sankyo Company Limited Compositions for improving lipids in blood
AR040588A1 (en) 2002-07-26 2005-04-13 Schering Corp PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUGHES DAVID E ET AL: "Involvement of the mevalonate pathway in osteoclast apoptosis and the mechanism of action of bisphosphonates.", BONE (NEW YORK), vol. 20, no. 4 SUPPL., 1997, 25th European Symposium on Calcified Tissues;Harrogate, England, UK; April 25-29, 1997, pages 110S, XP002172609, ISSN: 8756-3282 *
RUDEL T: "CASPASE INHIBITORS IN PREVENTION OF APOPTOSIS CASPASEINHIBITOREN ZUR PRAEVENTION VON APOPTOSE", HERZ,URBAN UND VOGEL, MUENCHEN,DE, vol. 24, no. 3, 1994, pages 236 - 241, XP001009833, ISSN: 0340-9937 *
See also references of WO9966930A1 *
WU J C ET AL: "IRREVERSIBLE CASPASE INHIBITORS: TOOLS FOR STUDYING APOPTOSIS", METHODS: A COMPANION TO METHODS IN ENZYMOLOGY,ACADEMIC PRESS INC., NEW YORK, NY,US, vol. 17, no. 4, 1999, pages 320 - 328, XP001000619, ISSN: 1046-2023 *

Also Published As

Publication number Publication date
EP1089732A1 (en) 2001-04-11
AU4699099A (en) 2000-01-10
WO1999066930A1 (en) 1999-12-29
CA2336192A1 (en) 1999-12-29
JP2002518449A (en) 2002-06-25

Similar Documents

Publication Publication Date Title
IL112593A0 (en) Methods for inhibiting bone loss and lowering serum cholesterol
HK1048949A1 (en) Method and composition for the treatment of scars
EP1083835A4 (en) Methods and devices for vascular surgery
HK1031174A1 (en) Compositions and methods for treating diabetes
AU6872498A (en) Method and composition for skin treatment
EP1217963A4 (en) Devices and methods for treating tissue
NZ514350A (en) Compositions and methods for effecting the levels of cholesterol
EP1022945A4 (en) Method and formulation for treating vascular disease
AU3387599A (en) Methods and compositions for tissue regeneration
IL142906A0 (en) Methods and compositions for treating or preventing peripheral neuropathies
IL115405A0 (en) Compositions and methods for treating mast-cell mediated conditions
ZA988016B (en) Compounds methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
EP1109548A4 (en) Compositions and methods for treating and preventing bone diseases using tocotrienols
ZA981600B (en) Methods and compositions for treating stickies
EP1089731A4 (en) Compositions and methods for treating elevated blood cholesterol
AU5594398A (en) Methods and compositions for preventing and treating bone loss
HUP0200829A2 (en) Agents and method for treating keratinous fibres
EP1089732A4 (en) Compositions and methods for treating elevated blood cholesterol
AU5791698A (en) Methods and compositions for preventing and treating bone loss
GB9817167D0 (en) Compositions and methods for treating elevated blood cholesterol
GB9817174D0 (en) Compositions and methods for treating elevated blood cholesterol
AU5169200A (en) Methods and compositions for treating breakthrough pain
AU5097099A (en) Methods and compositions for cancer treatment
GB9812941D0 (en) Method of treatment
AU5257198A (en) Compositions and methods for treating type ii diabetes involving hnf-4

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010124;LT PAYMENT 20010124;LV PAYMENT 20010124;MK PAYMENT 20010124;RO PAYMENT 20010124;SI PAYMENT 20010124

A4 Supplementary search report drawn up and despatched

Effective date: 20010806

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20011120

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020603